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Human breast cancer cells contain a phosphoramidon-sensitive
metalloproteinase which can process exogenous big endothelin-1 to
endothelin-1: a proposed mitogen for human breast fibroblasts
KV Patel and MP Schrey
Unit ofMetabolic Medicine, St Mary's Hospital Medical School, Imperial College ofScience, Technology and Medicine, London
W2 IPG, UK.
Sary Endothei-1 (ET-I) levels are elvated in human breast tumours compared with normal and
benign tissues, and in the presence ofinsuin-hlke growth factor I (IGF-I) ET-I is a potent mitogen for human
breast fibroblasts. In this study we have examied the ability ofintact human breast cancer cell lines to process
exogenously added big ET-I (1-38) to the active mature ET-I peptide by using a specific radioimmu
assay. In both hormome-dpendent (MCF-7, T47-D) and hormone-independent (MDA-MB-231) breast cancer
cell lnes the putative endothehn-converting enzyme (ECE) exhibited apparent Mxichalis-Menten kinetics
when converting added big ET-I to ET-I. Both basal ET-I production and exogenously added big ET-I to
ET-I convesion were greatly reduced m all three cel lines in response to the metalloproteinase inhibitor
phosphoramidon but were insensitive to other classes ofprotease inhibitors. Inhibition was also observed when
cells were incubated in the presence of the divalent cation chelators 1,10-phenanthrohn and EDTA. In
MCF-7 cells the optimal pH for the ECE activity using a saponin cell permeabilisation procedure was found
to reside within a narrow range of 6.2-726. Our results indicate that human breast cancer cells contain a
neutral phosphoramidon-sensitive metalloproteinase which can process big ET-i to ET-I. In the breast this
converson could contnbute substantially to the local extracellular kvels of this proposed paracrie breast
fibroblast mitogen.
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Since the discovery of the potent vasoconstrictor ET-I from
the spent medium of porcine aortic endothelial cells (Yana-
gisawa et al., 1988) other interesting facets relating to this
peptide have emerged. It is now known that ET-1 is express-
ed and produced by both vascular and non-vascular cell
types. Indeed, several human tumour cell lines derived from
the breast, colon, pancreas (Kusuhara et al., 1990), endo-
metrium (Economos et al., 1992), cervix and larynx (Shichiri
et al., 1991) also release immunoreactive ET. Such a wide
range of cell types expressing ET-1 peptide suggests that it
probably has diverse physiological actions. In addition to its
role in the vasculature, where it regulates blood pressure by
modulating vascular tonus, ET-1 also promotes steroido-
genesis in Leydig tumour cells (Ergul et al., 1993), stimulates
the secretion of aldosterone (Cozza et al., 1989), nor-
adrenaline and adrealine (Boarder and Marriott, 1991),
inhibits renin release from the glomerulus (Rakugi et al.,
1988) and promotes proliferation in a number of cell types
(Battistini et al., 1993a).
Studies which have examined the sites of ET-l expression
and binding indicate that ET-1 acts predominantly as an
endocrine/paracrine mediator since in some tissues only ET-1
receptors are present while in other tissues ET-l-producing
cells are found adjacent to ET-1 receptor-expressing cells.
For instance, in breast tissue the epithelial cells express ET-1
whereas breast fibroblasts possess endothelin receptors (Baley
et al., 1990). Thus, the ET-1 released from the breast epi-
thelial cells may act in a paracrine fashion on neighbouring
stromal tissue. An autocrine action of ET-1 has also been
recently suggested by Shichiri et al. (1991), who found that
two ET-l-producing epithelial cancer cell lines could be
mitogenically stimulated by the addition of ET-1 and inhi-
bited by an endothelin polyclonal antibody.
Molecular studies involving screening the human genomic
DNA library have revealed the presence of a family of ET-1
related peptides (ET-1, -2 and -3), all 21 amino acids in
length. It appears that all three isopeptides are encoded by
distinct genes on separate chromosomes (Inoue et al., 1989).
Evidence suggests that these ET-1 peptides are regulated
independently in a tissue-specific manner (Rubanyi and
Parker-Botelho, 1991). From the predicted prepro-ET-1
sequence, together with the known amino acid sequence of
big ET-1 (1-38), the processing steps for the production of
mature ET-1 have been proposed. Initialy the conversion of
the 212 amino acid prepro-ET-1 to big ET-1 is thought to
involve a pair of dibasic endopeptidases and carboxypep-
tidases. This is followed by the conversion of big ET-1 to
ET-1 by an unidentified putative ECE which catalyses an
unusual proteolytic cleavage between the Trp-21 and Val-22
bond ofbig ET-1. This unusual processing step has also been
reproduced in heterologous systems, such as in COS (Dilella
et al., 1991) and baculovirus-infected insect cells (Benatti et
al., 1992).
To date several candidates for this putative ECE have been
proposed. These include the cathepsin D-like (Sawamura et
al., 1990) or cathepsin E-like aspartic protease (Lees et al.,
1990), the soluble phosphoramidon-sensitive (Takada et al.,
1991) and -insensitive metalloproteinase (Matsumura et al.,
1991) and a membrane-bound phosphoramidon-sensitive
metalloproteinase (Ohnaka et al., 1993). From these and
numerous other studies conducted so far the emphasis now
appears to be directed towards the neutral phosphoramidon-
sensitive metalloproteinase described by Ohnara et al. (1993)
as being the likely physiologically relevant enzyme involved
in big ET-1 processing. An ECE from rat endothelial cells
has been recently cloned and functionally expressed (Shimada
et al., 1994) and has properties coinciding with those of the
enzyme from porcine aortic endothelium (Ohnaka et al.,
1993). The subcellular location of this ECE is at present
uncertain. A recent report shows that the majority of the
membrane-bound phosphoramidon-sensitive ECE in rat lung
is located in the Golgi complex (Gui et al., 1994), consistent
with a role in intracellular processing. However, a similar
ECE in the endothelial cell line EAHY 926 is present in the
plasma membrane (Waxman et al., 1994).
We report here studies conducted to identify and charac-
tense the human breast cancer cell ECE (BCC-ECE), which
can process big ET-1 to ET-1, a 'competence-type' growth
factor for human breast fibroblasts (Schrey et al., 1992).
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Cell lines
MCF-7 cells were kindly provided by Dr Marc Lippman
(Vincent T Lombardi Cancer Research Institute, Washing-
ton, USA), T47-D cells from (National Cell Bank at Porton
Down, UK) and MDA-MB-231 cells from Dr Joyce Taylor
(Imperial Cancer Research Fund, Lincolns Inn Field,
London). All cell ines were roufinely grown at 37C in
25 cm2 flasks conta ning full growth medium coning of
Eagle's minimal essential medium (EMEM) containing
20mM HEPES and supplemented with glutamine (2mM),
non-essential amino acids (MCF-7 and T47-D cells), insulin
(lOpgml-), peicilin (100 Uml-'), streptomyn(100pgml-)
and 5% fetal calf serum.
Chenicals
Endothelin-l, -2 and -3 and big ET-1 (1-38) were bought
from Cambridge Research Biochmials, Northwich,
Cheshire, UK. Phosphoramidon, bestatin, E-64, amastatin,
pepstatin A, phenyl methyl sulphonyl fluoride (PMSF), 1,10-
phenanthohne and saponin were purchased from Sigma,
Poole, Dorset, UK.
Treatments and collection ofspent mediumfor ET-J
inmznoradiometric assay
Cells wem grown in 25 cm2 flasks in full growth medium until
they were approximately 70% confluent. The medium was
then removed and the cells washed once with serum-free-
EMEM (SF-EMEM) containing 0.3% bovine serum albumin
(BSA) followed by incubation overnight in the same medium.
After 24 h the medium was discarded and 2 ml of the SF-
EMEM-containing treatments were added to each flask. The
spent medium was reoved at the end of the treatment
period and either assayed immiately or stored at
-20C.
After removal of the spent medium, cell counts were carried
out on each flask by counting cell nuclei released using a
Coulter counter (Butler et al., 1981). These counts were used
to normalise ET-1 production values obtained after the
immunoradiometric assay.
Sapoin permeabiisation ofMCF-7 cells
Since we are uncertain of the cellular location of the BCC-
ECE activity described in this present study with intact cells,
we have employed permeabilised cells to investigate the effect
of pH on enzyme activity. A simple procedure which makes
use of the agent saponin to produce pores in the plasma
membrane of intact cells was developed. These pores are
produced as a result of the interaction of saponin with the
cholesterol molcules on plasma membranes, and so allows
the passage of small molecules and ions. Mitochondrial and
endoplasmic reticulum membranes, which have negligible
amounts of cholesterol, are unaffected and remain func-
tionally intact. Thus, this method can be used to study the
effect of pH on intracellular enzymes in a semi-intact
system.
MCF-7 cells grown in 12-well plates were kept in a
humidified incubator at 37C in an atmosphere of 100% air
until they were 80% confluent. Cells were then washed three
times in a medium resembling cytosol (MRC) pH 7.2,
modified from Burgess et al. (1983) (MRC = 20 mM sodium
chloride, I00mM potassium chloride, 5mM magnesum sul-
phate dihydrate, 25 mm sodium biarbonate, 0.96mm
sodium dihydrogen phosphate dihydrate) and containing
0.3% BSA. Cells were then incubated for 90 s in MRC
solution containing saponin (75 pgml-').
After this step the cells were im iately washed three
times with MRC solution and then incubated
with MRC solution (minus NaH2PO42H20) buffered at
the appropriate pH with either 20mM MES or 20 mm
HEPES. Using this permeabilisation procedure more than
95% of the cells took up trypan blue, indicating successful
dell permeabilisation. Permeabilised cells were then incubated
for 16h at room temperature in the appropriate buffered
MRC solution at the pH under investigation and in the
absence or presence of big ET-1 or big ET-1 plus phospho-
ramidon. At the end of the incubation period the spent
medium was removed and assayed for the presence of ET-
1.
Enothelin-l imnsworadimetric assay
The measurement of ET-1 production was carried out in
96-well microtitre plates (Labsms Baigstoke, Hants,
UK) using a specific sold-phase-based sandwich assay. The
Microtitre plates were coated with the capture monoclonal
antibody 3G10 (lpgmh-') in 20mM Tris-HCl buffer
(pH 8.0). The plates were left overnight at room temperature,
after which they were washed four times with the phosphate-
buffered saline (PBS), and then 200 p1 of 0.05 M sodium
phosphate buffer (pH 7.4) containing 0.1 % BSA was added
to each well. After 2 h, the plates were washed four times
with PBS. Endotheln-I standards and experimental culture
superatants were then added to each well in a 100 1I
volume. This was followed by addition of 50pi of the "25I-
labelled polyclonal antibody IC4 (100 000 c.p.m. per well).
The wells were then mixed for 20 min using a plate shaker
and stored in a humidified box at 4-C for 20 h. After this
period the wells were washed four times with PBS containing
Tween 20 (0.05%, v/v). The wells were then cut and counted
in a Packard gamma-counter. In this assay, the cross-re-
activities of ET-2, -3 and big ET-1 (1-38) compared with
ET-1 (100%) were 100%, 50% and 0.01% respectively. The
sensitivity of this assay (2 x s.d. of zero dose estimate) was
0.5 fmol per well corresponding to 0.5 pmol 1-'. Sampks
from any one experiment were all masured together in the
same assay. The intra-assay coefficient of variation at 5, 30
and 80finol per well was 9.58%, 3.32% and 2.57% respec-
tively.
Identification of mmoreactive ETby high-performance
liqdchromatography (HPLC)
Near-confluent MCF-7 cells grown in 75 cm2 flascs were
washd once with SF-EMEM containing 0.3% BSA and then
incubated for 24 h in 10ml of fresh SF-EMEM. This
medium was disarded and a further 10 ml of SF-EMEM
containing treatments added. After 24 h the conditioned
medium was removed and acidified with 0.1% trifluoroacetic
acid (TFA) to pH.4.0 and then im dately stored at -20-C
until required. These samples were subsequently thawed and
4 ml applied to a Sep-Pak CI cartridge (Millipore, Watford,
UK) which had been preconditioned with 4ml of methanol
followed by 4ml of water. After the application of the
samples the cartridges were washed once with 5 ml of 0.1 %
TFA. The fraction containing the ET peptides were eluted
with 2ml of 80% acetonitrile containing 0.1% TFA. These
fractions were dried on a Savant Speedvac vacuum centrifuge
and reconstituted with HPLC buffer A (20% acetonitrile in
0.1% TFA). HPLC runs were conducted by injecting samples
onto a SuperPlus Pep-S 5gm column (Pharmacia, 4 x 250
mm) and eluting at a flow rate of 1 ml min-', using discon-
tinuous gradient starting with 100% buffer A and varying
buffer B (80% acetonitrile in 0.1% TFA) as follows: 100%
buffer A (0-5min); 0-50% buffer B (5-60min).
Fractions of 1 ml were collected in siliconised 1.5 ml
Eppendorftubes and dried on a Speedvac vacuum centriftuge.
Samples were subsequently resuspended in 150I 1 of 0.05 M
sodium phosphate buffer pH 7.4 containing 15 mM sodium
azide and assayed for the presence of ET-1.
Data analysis
All values are presented as means ± s.d. from individual
representative experiments. Significant differences between ex-
perimental groups were evaluated by Student's t-test. All
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expenments were performed in tnplicate unless otherwise
stated.
Results
Using intact monolayers of MCF-7 cells, the addition of
exogenous big ET-1 resulted in a time-dependent increase in
ET-1 measured in the spent cultured medium when compared
with basal release (Figure 1). Thus, at 1 h the ET-1 produced
from exogenous big ET-1 was 125% greater than basal
release, while at 24h this increase had risen by 320%.
To evaluate the differences in the conversion rates of big
ET-1 to ET-1 in the various cell lines, we studied the kinetics
of the ECE-mediated catalysis using intact cells. Under the
experimental conditions used the putative ECE in the MCF-
7, T47-D and MDA-MB-231 cell lines followed Michaelis-
Menten kinetics (Figure 2). After subtraction of basal ET-1
release from the MCF-7, T47-D and MDA-MB-231 cell lines
(1.65, 1.61 and 0.62 fmol 10-6cellsh-' respectively) the
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respective apparent K. values were found to be 7.01, 6.22
and 15.77 nM, while the corresponding V. rates were 11.36,
4.43 and 144.93 fmol 10-6 cells h-.
In MCF-7 cells the conversion of added big ET-1 to ET-1
was inhibited by the neutral metalloproteinase inhibitor
phosphoramidon in a dose-related manner with EC50 and
maximal effective inhibitory concentrations of 1 ;LM and
100 jm respectively (Figure 3). In addition, basal ET-1
release was also significantly inhibited by phosphoramidon,
indicating that ET-1 derived from either an endogenous or
exogenous big ET-1 source is most likely processed by the
same enzyme. Trypan blue dye exclusion studies and cell
number determinations after 24 h indicated no cytotoxic
effect of phosphoramidon up to at least 100 iM (data not
shown).
HPLC studies confirmed our finding of increased produc-
tion of ET-1 after addition of exogenous big ET-1 and
inhibition of this activity after treatment with phos-
phoramidon (Figure 4). Several other protease inhibitors
were also examined, including thiorphan (10011M), pepstatin
-a150- -6
0
co
0
_ 100 -
0
E
t0
= 50- 'a
0
II
**
3
Time (h)
Figue 1 Time course of big ET-1 to ET-1 conversion in MCF-7
cells. Intact MCF-7 cells grown in 25 cm2 flasks were incubated
without () or with ( ) big ET-1 (20nM) for various
periods of time. At the end of each incubation period the spent
medium was removed and assayed for ET-I. Cell numbers were
also determined and the results were subsequently normalised to
cell numbers. Results shown represent means ± s.d. of triplicate
incubations. *P<0.01 and **P<0.001 indicate increase in ET-1
production over basal release.
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Figue 3 Effect ofphosphoramidon on big ET-l to ET-1 conver-
sion in MCF-7 cells. Intact MCF-7 cells grown in 25 cm2 flasis
were incubated for 24 h either with (-) or without (0) big ET-1
(20 nM) in the prsence of various concentrations of phos-
phoramidon in SF-EMEM. The overlaying medium was then
removed and assayed for ET-1 production. Points respresent the
means ± s.d. of triplicate incubations. rP<0.001 indicates a
significant increase in ET-1 production compared with untreated
cells. *P<0.01 and **P<0.001 denote inhibition of added big
ET-1 to ET-1 conversion, whereas tP<0.01 and ttP<0.001
represent inhibition of basal ET-1 release.
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Fge 2 Lineweaver-Burk plot of various big ET-1 concentra-
tions on ECE activity in breast cancer cell ines. Intact cells were
incubated with different big ET-1 concentrations for 24 h in
SF-EMEM. Conversion to ET-1 was measured using the specific
immunoradiometric assay. In all cell lines, the apparent K. value
and V. for big ET-1 to ET-1 conversion were obtained from the
corresponding Lineweaver-Burk plots. Regression lines for all
plots were drawn according to a least-squares fit. 0, T47-D; *,
MCF-7; U, MDA-MB-231.
Fraction number
Figue 4 HPLC profiles of immunoreactive ET-1 produced in
MCF-7 cells after treatment with big ET-1 with or without
phosphoramidon. Conditioned media obtained after incubation
of cells with medium only (0), medium plus phosphoramidon
(10.tM) (0), big ET-1 (20nM) (0) or big ET-1 plus phos-
phoramidon (U) were extracted on C1 Sep-Pak cartridges and
subjected to reversed-phase HPLC using a discontinuous gradient
at a flow rate of I ml min 1. Fractions (1 ml) were collected and
assayed for ET-1. Elution positions of standard ET-1, ET-2,
ET-3 and big ET-1 (1-38) peptides are indicated.
\%
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0A (10 gM), captopril (10 JiM), amastastin (1 JiM), E-64 (5 tiM)
and PMSF (1 pM). None of the above inhibitors was found
to affect the conversion of big ET-l to ET-1 (data not
shown). Similar results were obtained with the T47-D and
MDA-MB-231 cell lines, consistent with the presence of a
similar ECE in these breast cancer cells.
When the metal ion requirement of the putative BCC-ECE
was examined in intact MCF-7 cells in the presence of SF-
EMEM (Ca2+ 1.8 mM), it was found that in three separate
experiments both EDTA and 1,10-phenanthroline greatly
reduced both basal ET-1 production and added big ET-1 to
ET-1 conversion (Figure 5). 1,10-Phenanthroline attenuated
the conversion of big ET-1 to ET-1 in a dose-related manner,
and at the highest concentration examined (200pM) a 38%
inhibition was observed, while EDTA (1 mM) completely
abolished big ET-1 processing. Again at the concentrations
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examined cell viability and cell numbers were not
significantly affected from untreated cells over the 24 h
incubation period.
The optimal pH for the BCC-ECE activity was examined
by incubating saponin-permeabilised cells with big ET-1 in
the absence and presence of phosphoramidon (10 1M). Our
results clearly show that the optimal pH for the putative
BCC-ECE under our experimental conditions resided within
a narrow range of 6.20-7.26 (Figure 6). Furthermore, this
activity was significantly attenuated by phosphoramidon.
Therefore, this enzyme appears to belong to the neutral
metalloproteinase class ofenzymes which is sensitive to phos-
phoramidon.
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Yamashita et al. (1991) recently reported that malignant
breast tumour tissue had much higher levels of immunore-
active ET-1 than either normal or benign cancer tissues.
Although no clear association was found between the levels
r1 1-1 I *¢s. ot Tl-1 present m breast tissue with the more commonly
used clinical prognostic indicators, the fact that higher levels
of ET-1 were found in tumour tissue suggests that ET-1 may
have an important role in the development and/or growth of
breast cancers.
Recent studies have suggested that ET-1 does not have a
direct effect on breast cancer cells but that it may in fact act
in a paracrine fashion on stromal breast fibroblasts. Thus,
ET-l-secreting breast epithelial cells have been shown to lack
ET-1 receptors, whereas cultured human breast fibroblasts
responded to ET-1 by stimulating inositol lipid breakdown
(Baley et al., 1990), and in the presence of IGF-I ET-1
200 1 behaved as a 'competence-type' growth factor by synergis-
iroline EDTA tically increasing DNA synthesis (Schrey et al., 1992). This (mm) mitogenic action of ET-1 on breast fibroblasts may contri-
bute in part to the marked desmoplastic response characteris-
nts on big ETll to ET tic of breast tumours. Interestingly, breast phyllodes
aCF-7cwils growu as tumours, rare mesenchymal tumours characterised by an
EDTA in the abusence abundant stromal proliferation, have been found to have
or 24 h. Data shown are much higher levels of ET-1 than either intra- or pericana-
is, and are typical of at licular fibroadenomas (Yamashita et al., 1992). Moreover,
al differences were deter- immunocytochemical staining for ET-1 in these phyllodes
notes stimulation versus tumours confirmed the epithelial cell origin of ET-1 produc-
and **P<0.0O1 denote tion.
d presence of big ET-I In this study we have examined the putative ECE that
regulates the conversion of big ET-1 to ET-1 in breast cancer
cell lines, with a view to determining whether this enzyme has
features common to the ECEs identified in other tissues and
if differences exist between various established human breast
cancer cell lines in their ability to process exogenous ET-1
precursor. Our results show that BCC-ECE is similar to the
ECEs identified in other tissues, including bovine aortic
endothelial cells (Okada et al., 1990) and rat lung (Takahashi
et al., 1993). That is to say this activity was inhibited by
metal chelators and phosphoramidon but was insensitive to
other classes of enzyme inhibitors, including pepstatin A, an
inhibitor of cathepsin D, an acidic protease implicated in big
ET-l processing in some systems (Sawamura et al., 1990) and
thiorphan, another inhibitor of neutral (metallo) endopep-
tidase. Furthermore, the optimal pH for the BCC-ECE was
determined to be between 6.2 and 7.2 which agrees with
7.0 7.5 8.0 recent studies on other cell types (Okada et al., 1990;
Takahashi et al., 1993; Waxman et al., 1994).
n permeabilised MCF-7 Michaelis-Menten kinetics on intact cells revealed that the
n to near confluence in MCF-7 and T47-D cell lines had a 2-fold greater affinity for
saponin (75 Lgmm-1) in the ECE than the hormone-independent MDA-MD-231 cells,
iosphate buffer, pH 7.2. while Vm,, rates indicated that the hormone-independent cell
iion buffered with either lines possess much more ECE activity than the hormone-
20 mm HEPES (pH 7.00, dependent cell lines, although this may just reflect differences
iated by the addition of in the availability of the precursor to the cell lines. Since our
(taining either ng ET- own studies show that basal ET-1 production by MDA-MD-
ts shown are the mean- 231 cells is low in companson with that of MCF-7 and
e typical of the results T47-D, the high capacity for ET-1 production by some if not
;. all breast tumours may reflect their ability to utilise extracel-
6.5
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lular big ET-1. The calculated apparent Km for BCC-ECE is
lower than that previously reported for ECE in endothelial
cells or lung (Ohnaka et al., 1993; Waxman et al., 1994).
Although the reasons for these differences are unknown, they
may be partly methodological. Thus, the degree of cell
confluency, medium composition and pH may affect conver-
sion to ET-1 (Phillips et al., 1992), as well as the use of intact
cells rather than subcellular or partially purified enzyme
preparations.
Although several studies have already reported that intact
cultures of vascular endothelial and smooth muscle cells are
capable of processing exogenous big ET-1 to ET-l (Ikegawa
et al.. 1991; Ohnaka et al.. 1991), it is unclear from both
these and our own studies just how this conversion is
accomplished, for instance whether it is mediated by an
endo-and or an ectoenzyme (Gui et al., 1993: Waxman et al..
1994).
Many studies have indicated that breast fibroblasts play an
important structural and physiological role in breast
epithelial cell function (Oka and Yoshimura, 1986; Reich-
mann et al.. 1989). Indeed, there is now evidence that breast
fibroblasts can stimulate the growth of breast cancer cells
under both in vivo (Gleiber and Schiffman, 1984; Horgan et
al., 1987) and in vitro conditions (Mukaida et al., 1991; van
Roozendall et al., 1992; Ryan et al., 1993), suggesting a
paracrine mode of action. Such an effect may be due partly
to the secretion of stimulatory fibroblast-derived growth fac-
tors such as IGF-I and IGF-II. Indeed, IGF-I, a mitogen for
breast cancer cells, has been shown to be produced by human
fibroblasts in vitro (Clemmons, 1984; Ankrapp and Bevan,
1993) and is expressed by breast stromal cells but not
epithelial cells (Yee et al., 1989). Moreover, Cullen et al.
(1991) have reported that fibroblasts grown from benign
breast tumours express predominantly IGF-I mRNA, where-
as fibroblasts grown from malignant breast tumours express
largely the IGF-II message. In situ hybridisation studies have
confirmed this change from IGF-I expression in normal and
benign breast tissue to IGF-II expression in malignant
tumours (Paik, 1992). Interestingly, in placental fibroblasts
ET-1 has been shown to stimulate the production of IGF-II
and IGF-binding proteins, but not IGF-I (Fant et al., 1992).
Thus, the high levels of ET-1 found in malignant breast
tumour tissue may be instrumental in the increased IGF-II
expression observed in the fibroblasts surrounding these
tumours.
In the context of such a paracrine loop the bioavailability
of ET-1 may represent an important event through which
breast fibroblasts regulate the function of the breast epithelial
cells. Therefore, the potential sources of ET-1 need to be
examined. In this respect, breast epithelial cells are a known
source of ET-1, and under in vitro conditions basal ET-1
levels can be augmented in response to prolactin (Baley et al.,
1990), glucocorticoids, bombesin (Schrey et al., 1992) and
interleukin 6 (Yamashita et al., 1993). Endothelin-l may be
also sequestered from the circulation, where concentrations
of 1.5 pM have been measured (Battistini et al., 1993b), since
in post-colostrum lactating mothers the levels of ET-1 in milk
are at least 1 -fold higher than that found in plasma (Lam et
al., 1990), consistent with an active uptake mechanism.
Finally, the ratio of big ET-1 to ET-1 found in the circula-
tion on average is generally found to be 2-4 (Battistini et al.,
1993b). and, assuming an active uptake mechanism, this
precursor then represents a readily available source of the
BCC-ECE.
In summary. we have identified in breast cancer cells the
presence of a phosphoramidon-sensitive neutral metallopro-
teinase which can process big ET-I to the breast fibroblast
mitogen ET-I. Thus, this enzyme may represent a therapeutic
target for those breast tumours, in which the stromal compo-
nent is important in the growth of the tumour.
Abbrewiatons ET-1. endothelin-1; ECE. endothelin-converting
enzyme; BCC. breast cancer cell. ir-ET-i immunoreactive endothelin-
1; IGF-I, insulin-like growth factor I; PBS. phosphate-buffered
saline: BSA. bovine serum albumin: TFA, trifluoroacetic acid: MES.
2--.V-morpholino)ethansulphonic acid; E-64. trans-epoxysuccinyl-L-
leucylamido-(4-guanino}-butane; HPLC. high performance liquid
chromatography, HEPES. 4-(2-hydroxyethyl)F-1-piperazine-ethanesul-
phonic acid.
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